vida: extract claims from 2026-05-07-pmc-glp1-psychiatric-systematic-review-2026

- Source: inbox/queue/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Systematic review confirms anhedonia data is absent from clinical trials despite widespread patient reporting, representing a genuine measurement infrastructure gap
+confidence: experimental
+source: Sa et al. (2026), systematic review finding anhedonia 'ABSENT from this review'
+created: 2026-05-07
+title: No validated clinical instrument currently captures GLP-1-induced anhedonia prospectively, creating a monitoring blind spot for the most clinically reported psychiatric adverse effect
+agent: vida
+sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
+scope: structural
+sourcer: Sa et al. (2026)
+supports: ["glp1-trials-lack-validated-anhedonia-measurement-infrastructure"]
+related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant"]
+---
+
+# No validated clinical instrument currently captures GLP-1-induced anhedonia prospectively, creating a monitoring blind spot for the most clinically reported psychiatric adverse effect
+
+This systematic review of 38 GLP-1 studies explicitly notes that 'anhedonia data: ABSENT from this review. Emotional blunting mentioned as potential adverse outcome but no incidence data. Anhedonia not characterized as distinct outcome.' This is not a knowledge gap but a measurement gap — no validated clinical instrument exists to prospectively capture anhedonia as a distinct outcome in GLP-1 trials. The review mentions 'emotional blunting' as a potential adverse outcome but provides no incidence data, dosing relationships, or temporal patterns. This creates a monitoring blind spot where the most frequently reported psychiatric adverse effect in clinical practice (anhedonia/'food noise quiet') has no standardized assessment tool, making it invisible to both clinical trials and post-market surveillance. The authors recommend 'rigorous psychiatric assessment' in future trials but do not specify instruments for anhedonia measurement, suggesting none are currently validated for this context.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -52,3 +52,10 @@ Dr. DeCaro and Dr. Dennis focus exclusively on restrictive eating disorder risk
 **Source:** Sa et al., Diabetes Obesity and Metabolism 2026
 
 Review finds GLP-1RAs 'show promise for REDUCING binge eating' with improvements in BES scores (-8.14 points vs. controls), while simultaneously noting 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns.' This confirms subtype-specific divergence: protective for BED, potentially harmful for restrictive subtypes.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Review documents 'reduced binge eating behaviors: mean BES score reduction -8.14 vs. controls' supporting the protective effect for binge eating disorder, while noting 'concerns regarding suicidality remain unresolved' which aligns with restrictive eating disorder risks.

domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md

@@ -10,23 +10,9 @@ agent: vida
 sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md
 scope: structural
 sourcer: Osmind
-related:
-- glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support
-- healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care
-- glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap
-- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
-- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
-- glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant
-- glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population
-- glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-supports:
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
-reweave_edges:
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|supports|2026-05-07
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07
+related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+supports: ["Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS"]
+reweave_edges: ["Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|supports|2026-05-07", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07"]
 ---
 
 # Primary care prescribers of GLP-1s at therapeutic weight-loss doses lack psychiatric competency to monitor for CNS effects, creating structural risk of anhedonia in patients without psychiatric support
@@ -38,4 +24,10 @@ GLP-1 receptors are densely distributed in VTA, nucleus accumbens, insula, and p
 
 **Source:** Psychopharmacology Institute Q1 2026 Review
 
-The Psychopharmacology Institute — a CME platform for practicing psychiatrists — now covers GLP-1 receptor agonists as emerging psychiatric pharmacology in quarterly clinical reviews. This signals that professional psychiatric education is actively incorporating GLP-1 into the psychiatric medication framework, moving beyond endocrinology-only prescribing. However, the review does not provide clinical screening protocols for psychiatrists evaluating patients already prescribed GLP-1s by other providers, indicating the competency gap persists at the protocol level despite conceptual recognition.
+The Psychopharmacology Institute — a CME platform for practicing psychiatrists — now covers GLP-1 receptor agonists as emerging psychiatric pharmacology in quarterly clinical reviews. This signals that professional psychiatric education is actively incorporating GLP-1 into the psychiatric medication framework, moving beyond endocrinology-only prescribing. However, the review does not provide clinical screening protocols for psychiatrists evaluating patients already prescribed GLP-1s by other providers, indicating the competency gap persists at the protocol level despite conceptual recognition.
+
+## Extending Evidence
+
+**Source:** Sa et al. (2026)
+
+Review provides specific clinical protocol recommendation: 'monthly check-ins with validated depression/suicidality tools' and 'psychoeducation for patients and caregivers.' This is described as 'as close to a formal clinical protocol as currently exists for GLP-1 psychiatric monitoring' but is not yet standard of care.

domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md

@@ -24,3 +24,10 @@ This systematic review of 80 RCTs (107,860 participants) plus large cohort studi
 **Source:** Gill et al., JAMA Psychiatry 2026
 
 MDD trial used oral semaglutide 14mg (therapeutic weight-loss dose range) and showed motivation improvement, contrasting with high-dose anhedonia reports. No dose-response curve was tested within the trial, leaving the therapeutic window undefined despite positive findings.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Systematic review notes 'heterogeneity in dosing, clinical indications, baseline psychiatric status' as a methodological limitation but provides no dose-response analysis for psychiatric outcomes, confirming the data gap despite mechanistic plausibility.

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -38,3 +38,10 @@ Sensitivity analysis of 2.06M VigiBase reports found NO eating disorder signals
 **Source:** Gill et al., JAMA Psychiatry 2026
 
 First RCT evidence that therapeutic doses in MDD population reduce motivation deficit (opposite of anhedonia induction). The population difference may be critical: MDD patients have baseline reward circuit dysfunction that GLP-1 normalizes, while metabolically healthy patients experience suppression from normal baseline.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026), 38-study systematic review
+
+Systematic review meta-analysis found 'modest antidepressant effects — meta-analyses suggest benefit, greater in type 2 diabetes populations' while simultaneously documenting '195% increased depression risk and 106% increased suicidal behavior risk in obesity patients' from large observational cohorts. The directional opposition is confirmed with the caveat that 'confounding by indication suspected' for the obesity population harm signal.

domains/health/glp1-psychotropic-co-medication-quadruples-suicidal-ideation-risk.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Pharmacovigilance data shows odds ratios of 4.45 for concurrent antidepressant use and 4.07 for benzodiazepines, creating an underappreciated drug-drug interaction risk
+confidence: experimental
+source: Sa et al. (2026), systematic review of 38 studies with pharmacovigilance analysis
+created: 2026-05-07
+title: GLP-1 receptor agonists quadruple suicidal ideation risk when combined with antidepressants or benzodiazepines
+agent: vida
+sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
+scope: causal
+sourcer: Sa et al. (2026)
+related: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-ai-alone", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1 receptor agonists quadruple suicidal ideation risk when combined with antidepressants or benzodiazepines
+
+Pharmacovigilance analysis within this systematic review identified elevated suicidal ideation odds ratios of 4.45 when GLP-1 receptor agonists are used concurrently with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a clinically significant drug-drug interaction that is structurally underdetected because GLP-1 prescribers in primary care may not have visibility into patients' psychiatric medication lists. The review notes that 'most RCTs excluded individuals with active suicidality or moderate-to-severe mood disorders — the population most at psychiatric risk,' meaning the interaction signal emerges from real-world pharmacovigilance rather than controlled trials. The authors recommend 'special caution for psychotropic medication co-users' but no formal contraindication or dose adjustment protocol exists. This creates a monitoring gap where the highest-risk population (those already on psychiatric medications) receives GLP-1 therapy without systematic psychiatric oversight.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -157,3 +157,10 @@ Parkinson's motor function improvement across 5 Phase 2 studies provides additio
 **Source:** EVOKE/EVOKE+ trials, Lancet 2026
 
 EVOKE failure in Alzheimer's disease with confirmed pathology defines the boundary condition for GLP-1 CNS efficacy: the drug works through reward/motivation circuits (VTA, NAcc, dopaminergic systems) for SUD and depression, but cannot modify molecular neurodegeneration cascades (amyloid/tau pathology) in established Alzheimer's disease. This mechanistic specificity strengthens the dopaminergic pathway argument by showing what GLP-1 CANNOT do.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Systematic review cites '29% alcohol reduction with dulaglutide' and notes 'potential benefits in SUD' as an emerging therapeutic application, supporting the mesolimbic dopamine mechanism hypothesis.

inbox/archive/health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: medium
 tags: [glp-1, psychiatry, systematic-review, depression, anhedonia, suicidality, meta-analysis]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content